Progress in Radiopharmacy: Developments in Nuclear Medicine, cartea 22
Editat de August P. Schubiger, Gerrit Westeraen Limba Engleză Hardback – 31 dec 1991
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 1331.74 lei 6-8 săpt. | |
SPRINGER NETHERLANDS – 25 sep 2012 | 1331.74 lei 6-8 săpt. | |
Hardback (1) | 1338.49 lei 6-8 săpt. | |
SPRINGER NETHERLANDS – 31 dec 1991 | 1338.49 lei 6-8 săpt. |
Din seria Developments in Nuclear Medicine
- 5% Preț: 346.15 lei
- 5% Preț: 3031.94 lei
- 5% Preț: 1041.90 lei
- 5% Preț: 356.43 lei
- 5% Preț: 2005.88 lei
- 5% Preț: 354.09 lei
- 5% Preț: 1343.93 lei
- 5% Preț: 1338.54 lei
- 5% Preț: 618.29 lei
- 5% Preț: 350.26 lei
- 5% Preț: 679.58 lei
- 5% Preț: 673.11 lei
- 5% Preț: 348.37 lei
- 5% Preț: 673.81 lei
- 5% Preț: 2017.97 lei
- 5% Preț: 677.61 lei
- 5% Preț: 1039.31 lei
- 5% Preț: 677.33 lei
- 5% Preț: 1046.94 lei
- 5% Preț: 349.04 lei
- 5% Preț: 670.86 lei
- 5% Preț: 1036.19 lei
- 5% Preț: 344.16 lei
- 5% Preț: 1040.04 lei
- 5% Preț: 1039.48 lei
- 5% Preț: 1041.19 lei
- 5% Preț: 1038.12 lei
- 5% Preț: 684.21 lei
- 5% Preț: 363.38 lei
- 5% Preț: 342.99 lei
- 5% Preț: 356.69 lei
- 15% Preț: 557.00 lei
- 5% Preț: 359.91 lei
- 5% Preț: 355.66 lei
- 5% Preț: 349.73 lei
Preț: 1338.49 lei
Preț vechi: 1408.93 lei
-5% Nou
Puncte Express: 2008
Preț estimativ în valută:
256.21€ • 275.47$ • 213.59£
256.21€ • 275.47$ • 213.59£
Carte tipărită la comandă
Livrare economică 19 decembrie 24 - 02 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780792315254
ISBN-10: 0792315251
Pagini: 228
Ilustrații: XIII, 228 p.
Dimensiuni: 155 x 235 x 16 mm
Greutate: 0.53 kg
Ediția:1992
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Nuclear Medicine
Locul publicării:Dordrecht, Netherlands
ISBN-10: 0792315251
Pagini: 228
Ilustrații: XIII, 228 p.
Dimensiuni: 155 x 235 x 16 mm
Greutate: 0.53 kg
Ediția:1992
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Nuclear Medicine
Locul publicării:Dordrecht, Netherlands
Public țintă
ResearchCuprins
1. Future development of radiopharmaceuticals.- One: Brain receptor ligands.- 2. Necessary conditions for a multicenter study with a new radiopharmaceutical. Example: 123 I-Iomazenil.- 3. Design and evaluation of new receptor ligands exemplified by recent developments in the pharmacology of the benzodiazepine receptor.- 4. Studies on substituted benzamides as brain dopamine receptor imaging agent.- Two: Technetium-99m and other radionuclide generators.- 5. Cell labeling in radiopharmacy: what can radiolabeled monoclonal antibodies offer?.- 6. Automated systems for the preparation of Tc-kits in hospitals.- 7. New radiopharmaceuticals based on Technetium.- 8. The development of new radionuclide generator systems for nuclear medicine applications.- Three: Positron Emission Tomography.- 9. Production and application of oxygen-15; radiopharmacy aspects.- 10. Clinical aspects of positron emission tomography.- 11. Carbon-11 radiopharmaceuticass - radiopharmacy aspects.- 12. Production and distribution of 18F-radiopharmaceuticals - 2-deoxy-2[18F]fluoro-D-Glucose — radiopharmaceutic aspects.- 13. Preclinical data necessary to assess PET examinations.- Four: Rules and regulations.- 14. EEC directives and radiopharmaceuticals: the point of view of the radiopharmaceutical industry.- 15. European regulations and guidelines for the registration of radiopharmaceuticals.- 16. General guidelines for the quality assurance and quality control of short-lived radiopharmaceuticals.- 17. Legal and regulatory aspects of PET radiopharmaceuticals in the USA.- Five: Education.- 18. The development of a co-ordinated training programme in radiopharmacy in Europe.- 19. Experiences in postgraduate education of radiochemists and radiopharmacists at Berlin- Buch.- Six: Appendix.- 20. Monoclonalchimeric antibodies to HIV-1 - Clinical perspectives.- 21. Tracer technique - the Swiss story.
Recenzii
'...results in a publication that should serve as a useful resource for radioharmacists, radiopharmaceutical scientists, and nuclear medicine clinicians working in academic and research environments.' Clinical Nuclear Medicine Sep. 1992